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Abstract 
This paper presents chemotherapy scheduling of cancer patients using type 1 and type 2 fuzzy logic controllers which are optimized 
by genetic algorithm. To handle the uncertainties of the model, we introduce a method to adjust the foot print of uncertainty (FOU) 
in interval type 2 (IT2) fuzzy systems based on the amount of uncertainty. Based on previous researches, type two fuzzy logic is 
more effective than type 1 in handling uncertainties in a model. According to this fact, proposed method tries to change the FOU 
of fuzzy sets adaptively based on the amount of uncertainty in counting tumor cells which always exist in real world. In addition, 
we have introduced two new indices to evaluate the results. Simulation results show that the proposed method can control the drug 
regimens better than IT2 and type 1 (IT1) fuzzy controllers. 
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1. Introduction    
Cancer is one of the most dangerous diseases which causes many deaths every year. Although new medical methods 
such as gene therapy and immunotherapy have been developed by scientists in recent years, these methods are still in 
their infancy. Different ways such as surgery, chemotherapy, radiation, and hormone therapy have been used in 
treatment of cancer. Chemotherapy is still one of the most effective methods in this field although it has many side 
effects such as toxicity and drug resistance [1]. Therefore the dosage of the therapy must be carefully adjusted in order 
to cause the minimum damage to healthy tissue whilst killing a maximum number of tumor cells [2]. In this field, 
feedback control theory can be applied to optimize the dosage of the therapy. Different approaches are introduced in 
modelling of the growth of tumor and normal cells. Some of these models were based on cellular automata [3-4] and 
some of them are introduced based on PDE’s and cellular automata [5-6].  
Mathematical models and control theories can be employed to improve the quality of treatment and obtain 
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systematic strategies of drug delivery. In one of the first efforts in this way, Swan used a logistic growth model to 
optimize the drug delivery of treatment procedure [7]. Later, Martin developed an optimal controller to schedules the 
drug delivery for a patients [8]. Competition model of cancer tumor based on immune system response and drug 
therapy which includes tumor cells, immune cells, host cells and drug interaction has been introduced by Pillis where 
optimal control theory was used to optimize chemotherapy regimens [9].Neural network was applied in a study for 
optimizing drug delivery based on feedback linearization by Floares [10]. Maximizing the effectors cells and 
interleukin-2 concentration has been considered in drug delivery optimization by Burden [11]. Lyapunov stability 
theorem has been applied in a closed loop control system proposed by Ghaffari to push the system to the area with 
smaller tumor cells [12]. Fuzzy logic was also applied in dosage optimization by Khaloozade [13]. Gompertzian model 
of tumor growth was used in optimization a cost function which considered the number of tumor and healthy cells 
simultaneously. Recently, a multi approach model introduced by Westman et al [1] has been used by Batmani and 
Khaloozade [15]. In this model a compartmental model was extended to appropriately describe drug resistance and 
two constraints were imposed on the value of the anticancer drug dynamics to avoid toxicity [14]. In this paper, we 
propose a simple method to adjust the footprint of uncertainty (FOU) of IT2 adaptively (called AIT2) based on the 
amount of uncertainty generated in counting the number of tumor cells.  
This paper is organized as following. The second section provides an overview to the mathematical frameworks 
including patient’s model and adjustable interval type 2 fuzzy controllers. Proposed model of the system is introduced 
in the third section. Simulation results are demonstrated in the fourth section and finally conclusions are discussed in 
the last section. 
2. Mathematical Framework 
2.1. Westman’s Model  
In Westman’s model each cell has four phases (called G1, S, G2 and M) in its life cycle. In G1, protein and RNA 
synthesis are active and consequently DNA is produced in phase S. In G2 phase, duplicated chromosomes are 
condensed and finally nuclear and cytoplasmic divisions occur in phase M. Based on the cell cycle, tumor cells which 
might be sensitive or resistant to the drug are divided into the two groups P and C in Westman’s model. Four 
compartments are defined which compartments Ps and Pr belong to the group P (sensitive and resistant cells 
respectively) and compartment Cs and Cr belong to the group C (sensitive and resistant cells respectively).Dynamic 
equations (1) describe the mathematical models of these compartments and their interactions. 
 
ௗ௉ೞ(௧)
ௗ௧ = ቀ൫1 −ߙ௦ − ߤ௉ೞ஼ೝ − ߤ௉ೞ௉ೝ൯ ௦ܲ(ݐ) + ߤ௉ೝ௉ೞ ௥ܲ(ݐ)ቁܨ + ߚ௦ܥ௦(ݐ)− ߜ௉ೞ ௦ܲ(ݐ) + ቀ−ߤ௉ೞ௉ೝ,೏ ௦ܲ(ݐ) + ߚ௦,ௗܥ௦(ݐ)−
  ܭ௣,ௗ ௦ܲ(ݐ)ቁܹ(݀ݎݑ݃)  
ௗ௉ೝ(௧)
ௗ௧ = ቀ൫1− ߙ௥ − ߤ௉ೝ஼ೞ − ߤ௉ೝ௉ೞೝ൯ ௥ܲ(ݐ) + ߤ௉ೞ௉ೝ ௦ܲ(ݐ)ቁܨ + ߚ௥ܥ௥(ݐ)− ߜ௉ೝ ௥ܲ(ݐ) + ቀ−ߤ௉ೞ௉ೝ,೏ ௦ܲ(ݐ) + ߚ௥,ௗܥ௥(ݐ)−
ܭ௣,ௗ ௦ܲ(ݐ)ቁܹ(݀ݎݑ݃)  
ௗ஼ೞ(௧)
ௗ௧ = ቀߙ௦ ௦ܲ(ݐ) + ߤ௉ೝ஼ೞ ௥ܲ(ݐ)ቁܨ − ߚ௦ܥ௦(ݐ)− ߜ஼ೞܥ௦(ݐ)− ൫ߚ௦,ௗ + ܭ஼,ௗ൯ܥ௦(ݐ)ܹ(݀ݎݑ݃)                                                                
ௗ஼ೝ(௧)
ௗ௧ = ቀߙ௥ ௥ܲ(ݐ) + ߤ௉ೞ஼ೝ ௦ܲ(ݐ)ቁܨ − ߚ௥ܥ௥(ݐ)− ߜ஼ೝܥ௥(ݐ)−ߚ௥,ௗܥ௥(ݐ)ܹ(݀ݎݑ݃)                                                                            
ܨ = ߣ log ( ௄௉ೞ(௧)ା௉ೝ(௧)ା஼ೞ(௧)ା஼ೝ(௧))               
(1)               
 
Parameters in the mathematical model are listed in table 1. Initial values of differential equations are ௦ܲ(0) = 1, 
௥ܲ(0) = ܥ௥(0) = ܥ௦(0) = 0 . (Note: if drug delivery time is considered as ݐ = 0, initial values will be changed. In this 
paper the initial values are considered 600 days after the cells are located in propagation phase which are about ௦ܲ(0) =
1.4 × 10ଵ଴, ௥ܲ(0) = 60,ܥ௥(0) = 15.5 ,ܥ௦(0) = 3.7 × 10ଽ ). Drug delivery in (1) is determined by following equation 
[15]:  
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ܹ(݀ݎݑ݃) = ݇(ܿ(ݐ) − ߪ)ܪ(ܿ(ݐ) − ߪ)        ,      ܪ(ݔ) = ቄ1;     ݔ > 0
0;     ݔ ≤ 0                
(2) 
 
where ܿ(ݐ) is drug concentration which can be realized such as  ௗ௖(௧)ௗ௧ = ݑ(ݐ) − ߛܿ(ݐ).   In this equation ߛ = 0.27 is 
a constant related to the drug elimination rate and ݑ(ݐ) is drug delivery rate which should be less than 2  
ܦܽݕିଵ݈݉ ݉݃⁄  at each cycle of chemotherapy [14].Total number of tumor cells is calculated by ܰ ଵܶ(ݐ) = ௦ܲ(ݐ) +
௥ܲ(ݐ) + ܥ௦(ݐ) + ܥ௥(ݐ).                                                                                                                   
2.2. Healthy Cells 
Gompertzian model is considered for the number of healthy cells. Proposed model is as follow [10]: 
 
ௗ௫(௧)
ௗ௧ = ߣ௫ log ቀ
௫ಮ
௫(௧)ቁݔ(ݐ) − ݇௫ܿ(ݐ)ݔ(ݐ)                
(3) 
 
where  ߣ௫ = 02128 ܦܽݕିଵ , ݇௫ = 0.78 ܦܽݕିଵ݈݉ ݉݃⁄ , ݔஶ = 10ଵଶ, ݔ(0) = 10ଵଶ and ݔ(ݐ) is the number of normal 
cells at time ′ݐ′. 
 
                                Table 1. Parameters of Westman’s Model 
Parameter  Parameter  Parameter  Parameter  
ࢻ࢙ = ࢻ࢘  0.2 ߤ௉ೞ஼ೝ  10ିଵଵ ߚ௦ 10ିଵ଴ ܦܽݕିଵ ߚ௦,ௗ 0.5݈݉ ݉݃⁄  
ࣆࡼ࢘࡯࢙ 10ିଵଵ ߜ௉ೞ = ߜ௉ೝ  0.0192 ܦܽݕିଵ ܭ 5 × 10ଵସ ܥ݈݈݁ݏ ߤ௉ೞ௉ೝ,೏ 5 × 10ିଽ  ݈݉ ݉݃⁄  
ࣆࡼ࢙ࡼ࢘ 10ିଵ଴ ߜ஼ೞ = ߜ஼ೝ 0.0173 ܦܽݕିଵ ߣ 0.00396 ܦܽݕିଵ ܭ௣,ௗ 0.98  ݈݉ ݉݃⁄  
ࣆࡼ࢘ࡼ࢙ 10ିଵ଴ ߚ௥ 10ିଵ଴ܦܽݕିଵ ߚ௥,ௗ 0.5  ݈݉ ݉݃⁄  ܭ௖,ௗ 0  ݈݉ ݉݃⁄  
2.3. Fuzzy Controllers 
Fuzzy systems and fuzzy controllers have been widely used in industrial and biological systems. Type-2 fuzzy logic 
was introduced by Zadeh [15] and has been applied in widespread applications in the recent years [16-19]. Type-2 
fuzzy set ܣሚ is characterized by a type-2 membership function ߤ஺෨(ݔ,ݑ) such as: 
 
ܣሚ = {൫(ݔ,ݑ), ߤ஺෨(ݔ,ݑ))ห∀ݔ ∈ ܺ,∀ݑ ∈ [0,1],ߤ஺෨(ݔ,ݑ) ∈ [0,1]}               
(4) 
 
To reduce the computational cost, interval type-2 fuzzy system (IT2-FS) which assumes interval membership 
grades for each type-2 fuzzy set, has been applied in this work [20]. Similar T2-FLS, the membership functions of 
IT2-FLS includes an uncertainty area, called footprint of uncertainty (FOU) (Fig. 1). 
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Fig. 1 Foot Print of Uncertainty 
The ݅௧௛  (݅ = 1,2, … ,ܴ) rule of a typical IT2-TSK model is as follow: 
 
ܫ݂ ݔଵ ݅ݏ ܣଵ௜  ܽ݊݀ ݔଶ ݅ݏ ܣଶ௜  ܽ݊݀…ݔ௡  ݅ݏ ܣ௡௜  ݐℎ݁݊ ݕ௜ = ܽ଴௜ + ܽଵ௜ ݔଵ + ⋯+ ܽ௡௜ ݔ௡ 
 
where ܣ௝௜ and ݔ௝  are ݆௧௛  (݆ = 1,2, … ,݊) IT2 membership function and ݆௧௛  input respectively, output coefficients  ܽ௞ത௜  
( ത݇ = 0,1, …݊) are IT2 factors in range [ܽ௞ത௜  , തܽ௞ത௜ ] to handle the uncertainty in the outputs. Final output is equal to:  
 
 
ܻ = ௒೗ା௒ೝଶ   where  ௟ܻ = min∀ ௒
∀ఓ
∑ ௬೔ఓ೔ೃ೔సభ
∑ ఓ೔ೃ೔సభ
 and  ௥ܻ = max∀ ௒
∀ఓ
∑ ௬೔ఓ೔ೃ೔సభ
∑ ఓ೔ೃ೔సభ
              
(5) 
Karnik-Mendel algorithm [16] should be applied to find ௟ܻ  and ௥ܻ   in (5). In above equation, we have ߤ௜ ∈ [ߤ௜ ,ߤ௜] , ௜ܻ ∈
ቂݕ௜ ,ݕ௜ቃ (ߤ௜ = min( ܣଵ௜ (ݔଵ),ܣଶ௜ (ݔଶ), … ,ܣ௡௜ (ݔ௡))  and ̅ߤ௜ = min( ̅ܣଵ௜ (ݔଵ), ̅ܣଶ௜ (ݔଶ), … , ̅ܣ௡௜ (ݔ௡)) ) where  ܣ௝௜ ൫ݔ௝൯  and  
̅ܣ௝௜൫ݔ௝൯ are minimum and maximum range in FOU of  ݆௧௛ membership function in ݅௧௛ rule of IT2-TSK model. In this 
paper, FOU is adaptively adjusted by an uncertainty factor ( ௙ܷ ) as determined in (14) for antecedent parts and 
consequent parts of the rules: 
 
 ܣ௝௜ ൫ݔ௝൯  = (0.8 − ௙ܷ) × ̅ܣ௝௜൫ݔ௝൯  and  ܽ௞ത௜ ∈ ൣ തܽ௞ത௜ × ൫0.8− ௙ܷ൯, തܽ௞ത௜ ൧, ( ത݇ = 1, …݊)              
(6) 
 
where ௙ܷ߳[0,0.6] is a bounded factor. It is clear that larger ௙ܷ gives larger area in FOU.  
3. Proposed Model 
Fig. 2 shows the proposed model for drug delivery controller with adaptive FOU. 
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Fig. 2 Block Diagram of the Proposed Model 
In this figure, fuzzy controller has two inputs: scaled error (ܧ) between reference amount of tumor cells (10ସ) and 
number of tumor cells estimated in the body of patient (ܰ ଵܶ) and change of error (∆ܧ) .Fuzzy rules are formed as (7): 
 
݂݅ ܧ ݅ݏ ܣ௘௜  ܽ݊݀ ∆ܧ ݅ݏ ܣ∆௘௜  ݐℎ݁݊ ܦௗ௜ = ܽ଴௜ + ܽଵ௜  ܧ + ܽଶ௜  ∆ܧ               
(7) 
 
where  ܦௗ௜  is drug delivery of ݅௧௛  rule, ܣ௘௜  and ܣ∆௘௜  are IT2 Gaussian membership functions of error and change of error 
respectively and ௝ܽ
௜s are output coefficients of consequent part of the rules. Error and change of error have been 
calculated every 14, 21 or 28 days after chemotherapy and scaled such that −1 ≤ ܧ ≤ 0 and −0.5 ≤ ∆ܧ ≤ 0.5  where 
are fuzzified by five fuzzy sets VL, L, M, H and VH for each of them (Note: since the number of tumor cells is often 
more than reference value (10ସ), error is a negative value). In this block diagram, it is supposed that the patient model 
is constructed by mathematical model plus a random uncertainty factor (ߙ௨) such that  ܰ ଵܶ = (1 + ߙ௨) × ܰ ଶܶ , ߙ௨ ∈
[−0.5  , 0.5 ] (this is because of some error in counting the tumor cells).  
As it is shown in equation (6), the FOUs of membership functions of error (ܧ), change of error (∆ܧ) and their 
coefficients in antecedent part are changed adaptively dependent to the uncertainty factor ௙ܷ_ா  and ௙ܷ_∆ா . The idea of 
adjusting the FOU is based on this fact: more uncertainty in the model, larger FOU. For this reason following equation 
has been used to adjust the FOUs by  ௙ܷ_ா  and ௙ܷ_∆ா: 
 
௙ܷ_ா = min(
|ே భ்ିே మ்|
ே మ்
=
หா೑ห
ே మ்
, 0.6)  ,    ௙ܷ_∆ா = min(|ߩ(ݐ) − ߩ(ݐ − 1)|, 0.6)               
(8) 
 
where ܰ ଵܶ  and ܰ ଶܶ are the number of tumor cells of patient and mathematical model of patient (which is expected to 
be true) respectively (Fig. 2). More difference between ܰ ଵܶ  and ܰ ଶܶ causes larger ௙ܷwhich in turn expands FOU by 
equation (7). In (8), ߩ(ݐ) is equal |ே భ்ିே మ்|ே మ்  in time ′ݐ′ where ߩ(0) = 0. Regardless of type 2 fuzzy model, genetic 
algorithm has been used to determine the parameters of fuzzy rules (Centers and standard deviations of Gaussian 
functions in antecedent parts and output coefficients ( ௝ܽ
௜) in consequent parts) by minimizing a cost function.  
4. Results  
GA has been used to set the unknown parameters of fuzzy model to optimize the following cost function: 
 
ܬ = wଵlog(ܬଵ) + ݓଶlog (ܬଶ)               
(9) 
 
where ܬଵ = ∫(ܰ ଵܶ − 10ସ)ଶ݀ݐ, ܬଶ = ∫(ݔ(ݐ) − 10ଵଶ)ଶ ݀ݐ, ݔ(ݐ) is the number of healthy cells in time ′ݐ′ (equation 3), 
10ସ  and 10ଵଶ  are desired amounts of number of tumor and healthy cells respectively (Note: we use logarithmic 
function in cost function to close ܬଵ and ܬଶ to each other). The weights ݓଵ  and ݓଶ  are coefficients that according to the 
patients are determined by physicians and ݓଵ + ݓଶ = 1 . In this paper, we set ݓଵ = 0.95  and ݓଶ = 0.05. IT1 (interval 
type 1) and IT2 membership functions of variables have been shown in Fig. 3. Model performance has been evaluated 
in three different chemotherapy period (14, 21 and 28 days). Type 1 (IT1), interval type 2 (IT2) and adaptive interval 
type 2 (AIT2) fuzzy models have been compared with two criteria: ܵ஽  (sum of delivered dosage in 84 days) and 
்ܴே  (rate of tumor cells to normal cells) determined by (18).  
 
்ܴே =
ே భ்(௧ୀ଼ସ)
௫(௧ୀ଼ସ)                
(10) 
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where ܰ ଵܶ(ݐ = 84) and  ݔ(ݐ = 84) are number of tumor and normal cells at the final day.  
Tumor and normal cells of three chemotherapy period by IT1 controller are shown in Fig. 4. With regard to some 
error in counting the number of tumor cells in real case, the difference between patient’s model and mathematical 
model is shown in this figure. The model is evaluated with three types of controllers IT1, IT2 and AIT2. Since ߙ௨  is a 
uniform random value, all types of controllers are evaluated 30 times and the mean of ܵ஽  and ்ܴே  are given in table 
2. As it is given in table 2, in all cases of controllers, ்ܴே of AIT2 model is less than the others which shows that the 
adaptive change in FOU could increase the dosage and decrease the number of tumor cells. In addition, the results 
shown in table 2, illustrate the superiority of IT2 model compared with IT1. 
             Table 2. Simulation Results at the Last Day (t=84) 
 Chemotherapy period=14 Chemotherapy period=21 Chemotherapy period=28  
IT1 IT2 AIT2 IT1 IT2 AIT2 IT1 IT2 AIT2  
ࡿࡰ 7.1634 7.5357 7.5716 5.6135 5.8045 5.8220 4.8302 4.9230 4.9275 × 1 
ࡾࢀࡺ 1.887 1.0325 0.95877 20.676 13.532 13.013 72.787 58.463 57.585 × 10ି଻ 
ࡺࢀ૚ 0.12956 0.067512 0.062451 1.8781 1.2140 1.1656 7.1042 5.6901 5.6036 × 10଺ 
࢞ 6.8644 6.5385 6.5134 9.0836 8.9713 8.9572 9.7610 9.7334 9.7321 × 10ଵଵ 
 
 
 
Fig 3. Membership Functions of Error (a and c) and Change of Error (b and d) 
5. Conclusion 
In this paper, adaptive FOU of type 2 fuzzy model (AIT2) has been considered. We proposed a method to adjust the 
FOU of membership functions regarded to the uncertainty in the model. Proposed method and new defined indices 
are evaluated by patient’s model under chemotherapy. The performance of IT2 and IT1 models are also compared in 
this paper. Results show the superiority of AIT2 compared to IT2 and IT1 models. In fact, it is shown that in the 
selected model, the area of FOU can be adaptively changed regarded to the amount of uncertainty to improve the 
defined indices. In future, proposed method can be evaluated by other bio or industrial systems. More researches are 
needed to verify the relation between area of FOU and uncertainty in the industrial model. 
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Fig.4 Number of normal cells (a, c, e) and tumor cells (b, d, f) for 14, 21 and 28 days of chemotherapy period. (b, d and f) show different between 
mathematical and patient model. 
References 
1. Westman JJ, Fabijonas BR, et al. Probabilistic Rate Compart-ment Cancer Model: Alternate Versus Traditional Chemotherapy Scheduling, 
Lecture Notes in Control and Information Sciences, Springer-Verlag, New York  2002: 491–506. 
2. Murray JM. Optimal control for a cancer chemotherapy problem with general growth and loss functions. Mathematical Biosciences 1990:98: 
273-287. 
3. Kansal AR, et al. Simulated brain tumor growth dynamics using a three-dimensional cellular automaton. Journal of Theoretical Biology 2000: 
367-382. 
4. Kansal AR, et al. Cellular automaton of idealized brain tumor growth dynamics. Biosystems 2000:55: 119-127. 
5. Anders ARA, Chaplain MAJ. Continuous and discrete mathematical models of tumor-induced angiogenesis. Bulletin of Mathematical Biology 
1998:60(5): 857_899.  
6. Enderling H., Anderson ARA. Mathematical modelling of radiotherapy strategies for early breast cancer. Journal of Theoretical Biology 
2006:241(1): 158_171. 
7. Swan G. Cancer chemotherapy: Optimal control using the Verhulst-Pearl equation. Bulletin of mathematical biology 1986:48: 381-404. 
8. Martin R. Optimal control drug scheduling of cancer chemotherapy. Automatica 1992:28: 1113-1123. 
9. De Pillis L, Radunskaya A. A mathematical tumor model with immune resistance and drug therapy: an optimal control approach. 
Computational and Mathematical Methods in Medicine 2001:3: 79-100.  
10. Floares A, et al. Adaptive neural networks control of drug dosage regimens in cancer chemotherapy, IEEE Int. Joint Conference on Neural 
Network, 2003:1: 154-159 
11. Burden TN, et al. Optimal control applied to immunotherapy. Discrete and Continuous Dynamical Systems Series B 2004: 4: 135-146. 
12.  Ghaffari A, Nasserifar N. Mathematical modeling and lyapunov-based drug administration in cancer chemotherapy. Journal of Electrical & 
Electronic Engineering 2009:5:151-158. 
13. Khaloozadeh H, Miri F. Optimal Fuzzy Dosage Programming for Patients Suffering from Breast Cancer in Stage IIB. IEEE Conference 
CIBEC08, 2008 
20 40 60 80
10
10
10
11
10
12
N
or
m
al
 C
el
ls
a) Chemotherapy after 14 Days
20 40 60 80
10
5
10
10
T
um
or
 C
el
ls
b) Chemotherapy after 14 Days
 
 
20 40 60 80
10
10
10
11
10
12
c) Chemotherapy after 21 Days
N
or
m
al
 C
el
ls
20 40 60 80
10
6
10
8
10
10
d) Chemotherapy after 21 Days
T
um
or
 C
el
ls
20 40 60 80
10
10
10
11
10
12
e) Chemotherapy after 28 Days
Days
N
or
m
al
 C
el
ls
20 40 60 80
10
6
10
8
10
10
f) Chemotherapy after 28 Days
Days
T
um
or
 C
el
ls
Patient 
Mathematical 
367 Hamid Mahmoodian et al. /  Procedia Computer Science  76 ( 2015 )  360 – 367 
14. Batmani Y , Khaloozadeh H. Optimal drug regimens in cancer chemotherapy: A multi-objective approach, Computers in Biology and Medicine  
2013:43:2089–2095 
15. Zadeh LA.  The concept of a linguistic variable and its approximate reasoning. Information Sciences. 1975:8:199–249. 
16.  Karnik N, Mendel J. Type-2 fuzzy logic systems. IEEE Trans. Fuzzy Syst 1999:7: 643–658. 
17.  Coupland S, John R. Geometric type-1 and type-2 fuzzy logic systems. IEEE Trans. Fuzzy Syst 2007: 15:3–15. 
18.  Wagner Ch, Hagras H. Toward general type-2 fuzzy logic systems based on z slices. IEEE Trans. Fuzzy Syst 2010: 18: 637–660. 
19.  Mendel J, Liu F, Zhai D.  plane representation for type-2 fuzzy sets: Theory and applications. IEEE Trans. Fuzzy Syst.  2009:17:1189–1207 
20. Mendel M, John R, Liu F. Interval type-2 fuzzy logic systems made simple.  IEEE Trans. Fuzzy Syst.  2006:14:808–821. 
